2017 ANNUAL REPORT

Mission: ***Sarcoma–Oma*** *educates and assists Sarcoma patients in their search for treatment options; helps fund their travel-related expenses when appropriate; and funds Sarcoma research.*

Vision: *Sarcoma patients worldwide derive comfort from the support provided by our Foundation.*

THE LINDA NOACK WIENER SARCOMA-OMA FOUNDATION

RECIPIENTS OF SARCOMA-OMA FOUNDATION GRANTS

Our grantees do not live in convenient proximity to the medical facilities which specialize in Sarcoma treatment. Thus, it has been our charge to reimburse the medical travel expenses of those depicted here.



A NOTE FROM DR. NEETA SOMAIAH, SARCOMA MEDICAL ONCOLOGY ASSISTANT PROFESSOR

In this past year, we studied the immune environment in most of the common and some of the rarer sarcoma subtypes. We prioritized eight subtypes based on their frequency and unmet medical need. Dr. Lazar's team created tissue microarrays TMAs with >100 patient samples from each of these subtypes. We completed the initial staining for immune infiltrate characterization to identify the presence and type of immune cells and PDL-1 staining in these tumors. ***The Sarcoma-Oma Foundation's funding helped accomplish part of this extensive immunophentotyping.*** This helped us with the design of our first check-point inhibitor (immunotherapy) study "Testing the efficacy of durvalumab and tremilumu-mab in multiple sarcoma subtypes," by helping us select the subtypes most likely to respond (dedifferentiated liposarcoma, undifferentiated pleomorphic sarcoma and angiosarcoma among others). This study has already enrolled 50 patients so far and we have noted responses in undifferentiated pleomorphic sarcoma, angiosarcoma and alveolar soft parts sarcoma patients. We are now analyzing the pre-treatment and on-treatment tissue from patients who responded vs. those that did not to identify biomarkers of response and mechanism of resistance. The preliminary results tell us that the immune infiltrate and PD-L1 staining at 6 weeks after treatment predicts the likelihood of response to these two agents. Given these results, we plan to perform additional staining on the TMAs of the various subtypes The University of Texas MD Anderson Cancer Center 2 to see if the newer immunotherapeutic check-point therapies (anti-CD73, OX40 agonists) will have a role in sarcoma. Our goal is to quickly translate this data to the clinic, by opening trials with novel immunotherapeutic agents in specific sarcoma subtypes where we have a rationale to support activity based on our preclinical work.

We now have four immunotherapy trials geared toward specific subtypes of sarcoma; and though it is exciting that some of these modalities that harness the body's own immune system are showing promise, there is still a lot of work that is yet to be done before we can understand what immune cells are capable of attacking sarcomas and which ones might actually be facilitating tumor growth, and which accelerators/ inhibitors of the immune system can play a role in sarcoma therapy.

We thank the Sarcoma-Oma Foundation for the support that made this research initiative possible.

LETTER FROM THE PRESIDENT

Serving as President of an organization supporting patients afflicted by Sarcoma was well beyond my imagination a few years past. The horrific reason which precipitated the establishment of the Sarcoma-Oma Foundation is hardly one to be celebrated but it has paved the way for supporting people reeling from this disease, and from that I have derived a great deal of satisfaction.

In 2017, we continued funding patients' medical travel, who live all over the country, to the few facilities which specialize in Sarcoma treatment. Their responses of appreciation continue to warm our hearts. Here's just one example: "Incredible – you have overwhelmed us with both your timing and your generosity. You are our bright star in our most tumultuous time!"

And, we continue to fund the first-ever Sarcoma Immunology Study at MD Anderson (further details on page 1).

In 2018, we will be adding a few targeted promotions/events which we anticipate will broaden our reach.

With appreciation for your continued support,



Gary Wiener
President, Sarcoma-Oma Foundation

BOARD OF DIRECTORS

Shelley Doran
Jill Gold
Dave Hagerman
Meredith Walsey
Aaron Wiener
Jaimey Wiener

ADVISORY

Craig Collins
Lisa Monetta

www.sarcoma-oma.org

314 West Oregon Avenue
Phoenix, AZ 85013

408-242-3339

The Sarcoma-Oma Foundation is a 501(c)3 organization with tax identification number 47-3857439.

STATEMENT OF ACTIVITIES	FY 2015	% of REVENUE	FY 2016	% of REVENUE	FY 2017	% of REVENUE
REVENUE						
DONATIONS	$ 148,489	87%	$ 102,496	70%	$ 139,250	87%
EVENTS	$ 22,600	13%	$ 41,581	28%	$ 19,998	12%
INVESTMENTS		0%	$ 2,001	2%	$ 998	1%
TOTAL REVENUE	$ 171,089	100%	$ 146,078	100%	$ 160,246	100%
PATIENT + RESEARCH FUNDING						
PATIENT FUNDING	$ 3,707	2%	$ 10,972	8%	$ 16,855	11%
RESEARCH FUNDING		0%	$ 25,000	17%	$ 25,000	16%
TOTAL FUNDING	$ 3,707	2%	$ 35,972	25%	$ 41,855	27%
EXPENSES						
EVENT COSTS	$ 67,038	39%	$ 94,814	65%	$ 69,588	43%
FUNDRAISING EXPENSES			$ 6,047	4%	$ 14,106	9%
ADMINISTRATIVE EXPENSES	$ 7,252	4%	$ 21,000	14%	$ 18,000	11%
TOTAL EXPENSES	$ 74,290	43%	$ 121,861	83%	$ 101,694	63%
NET PROFIT	$ 93,092	54%	$ <11,755>	-8%	$ 16,697	10%
NET ASSETS BEGINNING OF YEAR	-		$ $93,092		$ 86,337	
CHANGE IN ASSETS	$ 93,092		$ <11,755>		$ 16,697	
NET ASSETS END OF YEAR	$ 93,092		$ 81,337		$ 103,034	